Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report

Lapatinib in II linea dopo il doppio blocco pertuzumab-trastuzumab: un caso clinico

  • Valentina Magri Oncologia, Policlinico Umberto I, Roma - Italy
  • Simone Scagnoli Oncologia, Policlinico Umberto I, Roma - Italy
  • Gabriele Piesco Oncologia, Policlinico Umberto I, Roma - Italy
  • Giulia Pomati Oncologia, Policlinico Umberto I, Roma - Italy
Keywords: Lapatinib, Multifocal breast cancer, Hepatic metastases, Brain metastases

Abstract

We report the case of a young, 36-year-old patient diagnosed with multifocal breast carcinoma, undergoing neoadjuvant chemotherapy, surgery and adjuvant treatment. The patient presented an early recovery of liver disease after only 7 months of free interval. Histological reevaluation after liver biopsy revealed a HER2-positive disease, for which it was treated with first line chemotherapy including double anti-HER2 block. After 3 cycles the disease progressed at liver and encephalic level. It was therefore decided to treat brain localizations with whole-brain radiotherapy and to start a second line with capecitabine associated with lapatinib. This chemo-radiotherapy approach allowed to control the disease for 8 months. Following further progression (lymph node and bone), a third line was chosen with trastuzumab emtansine (TDM1). The encephalic disease remained stable for another 8 months, when due to visceral progression and worsening of clinical picture, TDM1 was interrupted and supportive therapies were started (Oncology).

.

Published
2018-10-31
How to Cite
1.
Magri V, Scagnoli S, Piesco G, Pomati G. Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report. Abtpn [Internet]. 31Oct.2018 [cited 5Jul.2020];4(1):185-90. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/131